Ketamine Tablet in Palliative Care

Palliative care — the specialized care focused on relief from symptoms, pain, and stress for people with serious illness — was one of the first clinical domains to embrace ketamine tablet. Its use in this setting predates the modern psychiatric applications by more than two decades and has the longest real-world experience base of any ketamine tablet application.

Why Ketamine Tablet Is Particularly Valuable in Palliative Care

The palliative care context makes ketamine tablet especially appropriate for several reasons:

IV access limitations: As illness progresses, IV access may become difficult or impractical for patients at home, in residential hospice, or in settings without infusion capabilities. The oral route provides effective analgesia without requiring IV placement.

Opioid-refractory pain: Cancer pain, neuropathic pain, and pain from tumor invasion of neural structures frequently becomes refractory to opioids alone as disease advances. NMDA receptor-mediated central sensitization contributes significantly to opioid-refractory cancer pain, and ketamine directly addresses this mechanism. For more on this topic, see our overview of ketamine tablet for chronic pain.

Opioid dose reduction: At a stage of illness when patients may be experiencing opioid-related side effects (constipation, sedation, cognitive impairment, opioid-induced hyperalgesia), adding ketamine can allow dose reduction while maintaining or improving pain control. This opioid-ketamine interaction is one of the most clinically valuable aspects of ketamine therapy.

Depression in terminal illness: Depression in patients with terminal illness is common, undertreated, and associated with significantly reduced quality of life. The rapid antidepressant effect of ketamine — avoiding the 4–8 week lag of conventional antidepressants — has special value in patients whose time is limited.

Home-based care: The oral route enables palliative ketamine to be administered at home, supporting patients' expressed preference to remain in familiar surroundings.

Pain Management Applications

Cancer-Related Neuropathic Pain

Cancer pain with neuropathic features — burning, shooting, stabbing pain from tumor invasion of neural structures, or chemotherapy-induced neuropathy — responds poorly to opioids alone but may respond well to NMDA-targeted agents.

Clinical evidence: Multiple prospective studies and systematic reviews support ketamine tablet as an adjunct for opioid-refractory cancer pain. A Cochrane systematic review found moderate-quality evidence supporting ketamine in refractory cancer pain, with clinically meaningful improvements in pain scores and opioid dose reduction in most trials.

Bone Metastasis Pain

Pain from bone metastases involves complex mechanisms including inflammatory, nociceptive, and neuropathic components. Ketamine tablet contributes to pain control in this setting, particularly for the neuropathic component.

Tumor Infiltration Pain

Pain from tumor infiltration of abdominal organs, chest wall, or neural structures is among the most difficult cancer pain to control. Low-to-moderate dose ketamine tablet (30–200 mg three times daily) often provides meaningful relief as part of a multimodal approach.

Mucositis Pain

For head and neck cancer patients undergoing radiation, severe mucositis creates excruciating oral pain. Ketamine tablet administered as an oral rinse/solution provides both topical and systemic analgesia, and some protocols use this approach specifically for mucositis management.

Depression and Psychological Distress in Terminal Illness

Depression and existential distress are among the most common and most undertreated problems in terminal illness. Standard antidepressants are often inappropriate in late-stage illness because:

• Response requires 4–8 weeks — time many patients do not have
• Side effects (anticholinergic, cardiac, sedating) are poorly tolerated in medically fragile patients
• Drug-drug interactions with polypharmacy are complex

Ketamine tablet's rapid antidepressant effect — typically within 24–72 hours — makes it uniquely suited to this context. Even patients with prognosis measured in weeks can benefit from improved mood, reconnection with meaning, and reduced suffering if treatment works within days.

Evidence

A landmark Australian randomized controlled trial (Iglewicz et al., 2015, building on work by Irwin, Parker, and colleagues) demonstrated that ketamine tablet produced significant reductions in depression scores in palliative care patients within 3 days of starting treatment, compared to placebo. Response rates were approximately 60–70% with very low doses (0.5 mg/kg ketamine tablet daily).

Multiple subsequent open-label studies in Australia, Canada, and the United Kingdom have confirmed ketamine's rapid antidepressant utility in palliative settings.

The Meaning-Enhancement Consideration

Some palliative care specialists and researchers have noted that the psychedelic and existential dimensions of ketamine's effects — at moderate doses that produce mild altered states — may facilitate:

• Enhanced capacity for meaningful reflection
• Increased sense of connection and acceptance
• Reduced fear of death (thanatophobia)
• Improved family and spiritual engagement

This observation intersects with the growing field of psychedelic-assisted therapy for existential distress in terminal illness (psilocybin research has generated the most data, but ketamine experiences some therapeutic parallels).

Dosing in Palliative Care

Palliative care ketamine dosing is typically more flexible and ranges more widely than psychiatric protocols, reflecting the diverse needs of this patient population.

Starting Doses for Pain

• Ultra-low: 10–20 mg 3–4 times daily (opioid potentiation, OIH treatment)
• Low: 30–60 mg 3 times daily (mild-moderate neuropathic pain adjunct)
• Moderate: 100–200 mg 3 times daily (severe refractory pain)
• High: 200–600 mg/day in divided doses (refractory cancer pain; requires close monitoring)

Starting Doses for Depression

• 0.5 mg/kg once daily (approximately 35–50 mg for a 70 kg patient)
• Titrate up to 1–2 mg/kg if initial response is inadequate
• Lower starting doses appropriate for frail or elderly patients

Special Formulations in Palliative Care

In palliative settings where swallowing becomes difficult:

• Oral liquid formulations (ketamine solution) can be taken by syringe
• Buccal or sublingual administration of liquid ketamine
• Rectal administration via suppository (bioavailability ~25–30%)
• Subcutaneous continuous infusion for very late-stage patients in whom oral route is lost

Integration with Opioid Therapy

Ketamine tablet is almost always used as an adjunct to, not a replacement for, opioid therapy in palliative care:

Opioid rotation: When rotating between opioids (due to tolerance or side effects), adding ketamine tablet facilitates the rotation by reducing sensitization to the new opioid.

Opioid dose reduction: Once ketamine is established at effective doses, reducing the opioid dose by 20–30% may be possible, often with improved pain control due to reduced OIH.

Preventing breakthrough pain: Some protocols use ketamine tablet to reduce the frequency of breakthrough pain episodes, reducing the need for frequent rescue opioid doses.

Monitoring Considerations in Palliative Care

Traditional monitoring approaches must be adapted for palliative care contexts:

Realistic goals: In late-stage illness, the goal is not cure or long-term organ health monitoring. The focus shifts to symptom burden assessment and quality of life.

Simplified monitoring: PHQ-4 or GDS-15 for mood; NRS for pain; functional assessment appropriate to the patient's capacity.

Bladder safety: In patients with life expectancy greater than 3 months, baseline urological assessment is still appropriate. In patients with very limited prognosis, this may be deprioritized based on clinical judgment.

Family involvement: In advanced illness, family and caregiver participation in monitoring is often more practical than patient self-report, particularly as cognitive function may decline.

Ketamine tablet in palliative care represents one of its most clearly indicated and well-evidenced applications — a setting where its benefits are most clinically compelling and where the pragmatic advantages of the oral route are most fully realized.

References

• StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
• PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
• MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
• NIMH: Depression — National Institute of Mental Health overview of depressive disorders, treatment-resistant forms, and emerging therapies
• WHO: Depression Fact Sheet — World Health Organization global data on depression prevalence, burden, and treatment approaches